Researchers at Vanderbilt-Ingram Cancer Center have discovered a drug target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
Oct 4, 2023
0
1
A multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ...
Sep 28, 2023
0
1
Vanderbilt University Medical Center (VUMC) neurologists and scientists, along with colleagues from Charité-Berlin University of Medicine, are reporting that the use of Deep Brain Stimulation (DBS) in a very specific location ...
Aug 2, 2023
0
27
Penicillin allergy affects more than 25 million people in the United States (up to 1 in 10 Americans) and has been shown to lead to particularly poor health outcomes in pregnant women and surgical patients. It is also a public ...
Jul 17, 2023
0
29
The U.S. government could save taxpayers between $228 million and $2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban ...
Jun 8, 2023
0
16
The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers ...
Jun 6, 2023
0
58
A study from Vanderbilt researchers has found that enhanced treatment support can help smokers who have more difficulty quitting because they are fast metabolizers of nicotine.
May 31, 2023
0
17
One of the most important advances in palliative care in oncology over the past 15 years has been the recognition that palliative care specialists can improve cancer patients' outcomes well before their end of life.
May 10, 2023
0
4
An exhaustive cost-benefit analysis of population genetic testing published in Annals of Internal Medicine concludes with a recommendation to U.S. health policymakers to adopt routine testing of adults ages 40 and under for ...
May 8, 2023
0
40
GLP1 receptor agonists—a class of diabetes medications—are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease. ...
May 8, 2023
0
43
